Sacubitril/Valsartan Ameliorates Inflammation and Oxidative Stress in Hypertensive Heart Disease by Upregulating CAMKK2 Protein and Modulating the AMPK / AKT / GSK ‐3β Axis
The Kaohsiung Journal of Medical Sciences · 2026
DOI: 10.1002/kjm2.70127 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Kaohsiung Journal of Medical Sciences, 2026. Verfasst von Yan-Jun Yang und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Practice, Tiyuzhongxin Street Community Health Service Center in Nankai District of Tianjin, Tianjin, China. Hauptthemen laut MEDLINE: Oxidative Stress, Calcium-Calmodulin-Dependent Protein Kinase Kinase, Glycogen Synthase Kinase 3 beta, AMP-Activated Protein Kinases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Sacubitril/valsartan (Sac/Val) has emerged as an effective compound with myocardium‐protective functions in experimental and clinical trials for heart failure. This study investigated the function of Sac/Val in hypertensive heart disease (HHD) and explored the underlying mechanism. Spontaneous hypertensive rats (SHRs) were used as an animal model of HHD. Sac/Val administration ameliorated pathological injury, fibrosis, cell apoptosis, inflammatory cytokine production, and oxidative stress in the myocardial tissues of HHD rats. Similar findings were observed in vitro, where Sac/Val treatment reduced inflammation, oxidative stress, and fibrosis‐related markers in Ang II‐challenged H9C2 cells. Calcium/calmodulin‐dependent protein kinase kinase 2 (CAMKK2) was identified as a target of Sac/Val which was downregulated in HHD models, and CAMKK2 protein levels were restored by Sac/Val treatment. Lentiviral vector‐induced CAMKK2 knockdown reduced the phosphorylation levels of AMPKα, AKT, and GSK‐3β, thereby negating the treatment effects of Sac/Val. Further treatment with AICAR, an AMPK agonist, significantly reactivated the AMPK/AKT/GSK‐3β cascade and alleviated inflammatory injury in both models. Collectively, this study suggests that Sac/Val ameliorates inflammation and oxidative stress in HHD by restoring the CAMKK2 protein and activating the AMPK/AKT/GSK‐3β cascade.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of General Practice, Tiyuzhongxin Street Community Health Service Center in Nankai District of Tianjin, Tianjin, China.
- Department of Internal Medicine, Tianjin Shuige Hospital, Tianjin, China.
ORCID-Profile: Yan-Jun Yang
Zitieren
APA
Yang, Y. J., & Li, J. S. (2026). Sacubitril/Valsartan Ameliorates Inflammation and Oxidative Stress in Hypertensive Heart Disease by Upregulating CAMKK2 Protein and Modulating the AMPK / AKT / GSK ‐3β Axis. The Kaohsiung Journal of Medical Sciences. https://doi.org/10.1002/kjm2.70127
Vancouver
Yang YJ, Li JS. Sacubitril/Valsartan Ameliorates Inflammation and Oxidative Stress in Hypertensive Heart Disease by Upregulating CAMKK2 Protein and Modulating the AMPK / AKT / GSK ‐3β Axis. The Kaohsiung Journal of Medical Sciences. 2026. doi:10.1002/kjm2.70127
BibTeX
@article{Yang2026,
author = {Yang, Yan-Jun and Li, Jiu-Sheng},
title = {Sacubitril/Valsartan Ameliorates Inflammation and Oxidative Stress in Hypertensive Heart Disease by Upregulating CAMKK2 Protein and Modulating the AMPK / AKT / GSK ‐3β Axis},
journal = {The Kaohsiung Journal of Medical Sciences},
year = {2026},
doi = {10.1002/kjm2.70127}
}
EUVIMED